Abstract Number: 1607 • 2016 ACR/ARHP Annual Meeting
The Development of a New Anti–Interleukin 6 Blocker for Rheumatoid Arthritis Patients
Background/Purpose: While interleukin-6 (IL-6) blockade with monoclonal antibodies is an established, clinically validated mechanism for the treatment of rheumatoid arthritis (RA), the need for significant…Abstract Number: 2252 • 2016 ACR/ARHP Annual Meeting
Estimated Cost of SLE Hospitalizations
Background/Purpose: Systemic lupus erythematosus (SLE) treatment comes at a high price, with both direct costs related to healthcare resource utilization and indirect ones related to…Abstract Number: 123 • 2015 ACR/ARHP Annual Meeting
An Economic Evaluation of Tofacitinib (Xeljanz) Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the US
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). An economic model was developed to evaluate the treatment…Abstract Number: 113 • 2015 ACR/ARHP Annual Meeting
Longitudinal, Incremental Direct Medical Costs of Giant Cell Arteritis for the First Five Years Following Diagnosis: A General Population-Based Cohort Study
Background/Purpose: Giant cell arteritis (GCA) is the most common form of adult vasculitis, but estimates of the healthcare costs of GCA are extremely scarce. We…Abstract Number: 2473 • 2015 ACR/ARHP Annual Meeting
Psycho-Socio-Economic Burdens of Childhood Onset Rheumatic Diseases on Families
Background/Purpose: Rheumatic diseases (RD) in children, being complex and chronic in nature, do not only pose physical insult to the affected child, but also psychological…Abstract Number: 2356 • 2015 ACR/ARHP Annual Meeting
Major Cardiovascular Events in Gout Patients with Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating on Allopurinol or Febuxostat (Uloric)
Background/Purpose: Xanthine oxidase inhibitors (XOI) reduce both urate levels and oxidative stress in the vasculature, both of which are cardiovascular disease (CVD) risk factors. However,…Abstract Number: 2160 • 2015 ACR/ARHP Annual Meeting
The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis: A Diagnostic Accuracy and Cost-Effectiveness Study
Background/Purpose: Giant cell arteritis (GCA) is a relatively common form of primary systemic vasculitis which if untreated can lead to permanent sight loss. It is…Abstract Number: 1688 • 2015 ACR/ARHP Annual Meeting
Trends in Hospitalizations and Charges for Ankylosing Spondylitis, 1993-2012
Background/Purpose: In the last two decades, tumor necrosis factor alpha (TNFα) inhibitors have been approved for use, and recommended as part of clinical treatment…Abstract Number: 1678 • 2015 ACR/ARHP Annual Meeting
Does the Level of Disease Control Achieved with Biologics Influence Overall Costs for Health Care and Work Loss in RA?
Background/Purpose: Numerous studies have modeled whether biologic drugs are good value for money in the treatment of RA, in terms of reducing health care use…Abstract Number: 1295 • 2015 ACR/ARHP Annual Meeting
Online Consultation for Rheumatic Disease Patients Based on Smart System of Disease Management (SSDM) Mobile Tools: A Study of Medical Economics
Background/Purpose: China has no primary medical care and referral system. Patients can choose any hospitals or any doctors they like to seek medical care. As…Abstract Number: 1270 • 2015 ACR/ARHP Annual Meeting
Low Socioeconomic Status As a Predictor of Long-Term Direct Medical Costs Following Diagnosis of Granulomatosus with Polyangiitis: A General Population-Based Cohort Study
Background/Purpose: Estimates of the healthcare costs of Granulomatosus with polyangiitis (GPA) and predictors of costs are scarce. In particular, while socioeconomic status (SES) is associated…Abstract Number: 1001 • 2015 ACR/ARHP Annual Meeting
What Is the Most Cost-Effective Physical Therapy Strategy to Treat Knee Osteoarthritis?
Background/Purpose: The American College of Rheumatology (ACR) strongly recommends exercise therapy as a first-line conservative treatment for individuals with knee osteoarthritis (OA).1 Evidence supporting manual…Abstract Number: 989 • 2015 ACR/ARHP Annual Meeting
Economic Evaluation of Lupus Nephritis in an International Inception Cohort: Comparing the Hospitalization, Medication, Dialysis, and Procedure Costs of Those with and without Nephritis
Background/Purpose: Little is known about the long-term costs of lupus nephritis (LN). The annual and long-term healthcare costs were compared between SLE patients with and…Abstract Number: 598 • 2015 ACR/ARHP Annual Meeting
Economic Impact of Decreasing Adalimumab and Etanercept Doses and Drug Monitoring in Patients with Rheumatoid Arthritis in Clinical Remission: Preliminary Study from a Local Biologics Unit
Background/Purpose: To evaluate the economic impact of adalimumab (ADL) and etanercept (ETN) dose reduction (by decreasing treatment frequency) and drug monitoring in patients with rheumatoid…Abstract Number: 555 • 2015 ACR/ARHP Annual Meeting
Outcomes Associated with Non-Medical Switching/Discontinuation of Anti-TNF Inhibitors Among Patients with Rheumatoid Arthritis
Background/Purpose: Patients with RA are often treated with anti-tumor necrosis factor (TNF) agents. However, patients with a stable response to anti-TNF therapy may discontinue or…
ACR Meeting Abstracts